Reprint

MERS-CoV

Edited by
December 2019
274 pages
  • ISBN978-3-03921-850-9 (Paperback)
  • ISBN978-3-03921-851-6 (PDF)

This is a Reprint of the Special Issue MERS-CoV that was published in

Biology & Life Sciences
Medicine & Pharmacology
Public Health & Healthcare
Summary
Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging zoonotic coronavirus. First identified in 2012, MERS-CoV has caused over 2460 infections and a fatality rate of about 35% in humans. Similar to severe acute respiratory syndrome coronavirus (SARS-CoV), MERS-CoV likely originated from bats; however, different from SARS-CoV, which potentially utilized palm civets as its intermediate hosts, MERS-CoV likely transmits to humans through dromedary camels. Animal models, such as humanized mice and nonhuman primates, have been developed for studying MERS-CoV infection. Currently, there are no vaccines and therapeutics approved for the prevention and treatment of MERS-CoV infection, although a number of them have been developed preclinically or tested clinically. This book covers one editorial and 16 articles (including seven review articles and nine original research papers) written by researchers working in the field of MERS-CoV. It describes the following three main aspects: (1) MERS-CoV epidemiology, transmission, and pathogenesis; (2) current progress on MERS-CoV animal models, vaccines, and therapeutics; and (3) challenges and future prospects for MERS-CoV research. Overall, this book will help researchers in the MERS-CoV field to further advance their work on the virus. It also has important implications for other coronaviruses as well as viruses outside the coronavirus family with pandemic potentials.
Format
  • Paperback
License and Copyright
© 2020 by the authors; CC BY license
Keywords
mouse model; hDPP4; MERS-CoV; pseudotyped virus; authentic virus; Middle East Respiratory Syndrome Virus; MERS-CoV; neutralizing monoclonal antibodies; MERS-CoV; MERS-CoV nucleocapsid protein; murine CD8+ T cell epitope; MVA vaccine; MERS-CoV; mechanism of action; small-molecule inhibitor; Drivers; MERS-CoV; Qatar; MERS-CoV; RBD; mutation; peptide; neutralizing antibody; combination; MERS-CoV; inflammation; pyroptosis; complement; MERS-CoV; fusion inhibitor; peptide; cell–cell fusion; HKU4; coronaviruses; SARS-CoV; MERS-CoV; spike proteins; animal model; prevention and treatment; Coronavirus; MERS-CoV; spike protein; receptor-binding domain; vaccines; therapeutics; lipidomics; UHPLC–MS; HCoV-229E; MERS-CoV; Middle East respiratory syndrome coronavirus; severe acute respiratory syndrome coronavirus; coronavirus spike glycoprotein; vaccine platforms; correlates of immunity; animal models; Coronavirus; MERS-CoV; receptor-binding domain; therapeutic antibodies; nanobodies; cross-neutralization; MERS-CoV; camels; vaccines; One Health; MERS-CoV; transmission; pathogenesis; host factors; DPP4; MERS-coronavirus; transmission; rabbits; n/a